Selected research
Industry Research
Osteoarthritis Autologous Chondrocyte Therapy Industry Research Report 2026
Market perspective
The global Osteoarthritis Autologous Chondrocyte Therapy market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Osteoarthritis Autologous Chondrocyte Therapy market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Osteoarthritis Autologous Chondrocyte Therapy market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Osteoarthritis Autologous Chondrocyte Therapy market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Osteoarthritis Autologous Chondrocyte Therapy include CO.DON GmbH, Japan Tissue Engineering, Orthocell and Vericel, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Osteoarthritis Autologous Chondrocyte Therapy market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Osteoarthritis Autologous Chondrocyte Therapy.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Osteoarthritis Autologous Chondrocyte Therapy Market by Company
CO.DON GmbH
Japan Tissue Engineering
Orthocell
Vericel
Osteoarthritis Autologous Chondrocyte Therapy Segment by Type
2nd Gen C-ACI
3rd Gen M-ACI
Osteoarthritis Autologous Chondrocyte Therapy Segment by Application
Primary Osteoarthritis
Secondary Osteoarthritis
Osteoarthritis Autologous Chondrocyte Therapy Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Osteoarthritis Autologous Chondrocyte Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Osteoarthritis Autologous Chondrocyte Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Osteoarthritis Autologous Chondrocyte Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Osteoarthritis Autologous Chondrocyte Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 2nd Gen C-ACI
- 3rd Gen M-ACI
Applications
- Primary Osteoarthritis
- Secondary Osteoarthritis
Companies covered
- CO.DON GmbH
- Japan Tissue Engineering
- Orthocell
- Vericel
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Osteoarthritis Autologous Chondrocyte Therapy by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 2nd Gen C-ACI
- 2.2.3 3rd Gen M-ACI
- 2.3 Osteoarthritis Autologous Chondrocyte Therapy by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Primary Osteoarthritis
- 2.3.3 Secondary Osteoarthritis
- 2.4 Assumptions and Limitations
3 Osteoarthritis Autologous Chondrocyte Therapy Breakdown Data by Type
- 3.1 Global Osteoarthritis Autologous Chondrocyte Therapy Historic Market Size by Type (2021-2026)
- 3.2 Global Osteoarthritis Autologous Chondrocyte Therapy Forecasted Market Size by Type (2027-2032)
4 Osteoarthritis Autologous Chondrocyte Therapy Breakdown Data by Application
- 4.1 Global Osteoarthritis Autologous Chondrocyte Therapy Historic Market Size by Application (2021-2026)
- 4.2 Global Osteoarthritis Autologous Chondrocyte Therapy Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Osteoarthritis Autologous Chondrocyte Therapy Market Perspective (2021-2032)
- 5.2 Global Osteoarthritis Autologous Chondrocyte Therapy Growth Trends by Region
- 5.2.1 Global Osteoarthritis Autologous Chondrocyte Therapy Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Osteoarthritis Autologous Chondrocyte Therapy Historic Market Size by Region (2021-2026)
- 5.2.3 Osteoarthritis Autologous Chondrocyte Therapy Forecasted Market Size by Region (2027-2032)
- 5.3 Osteoarthritis Autologous Chondrocyte Therapy Market Dynamics
- 5.3.1 Osteoarthritis Autologous Chondrocyte Therapy Industry Trends
- 5.3.2 Osteoarthritis Autologous Chondrocyte Therapy Market Drivers
- 5.3.3 Osteoarthritis Autologous Chondrocyte Therapy Market Challenges
- 5.3.4 Osteoarthritis Autologous Chondrocyte Therapy Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Osteoarthritis Autologous Chondrocyte Therapy Players by Revenue
- 6.1.1 Global Top Osteoarthritis Autologous Chondrocyte Therapy Players by Revenue (2021-2026)
- 6.1.2 Global Osteoarthritis Autologous Chondrocyte Therapy Revenue Market Share by Players (2021-2026)
- 6.2 Global Osteoarthritis Autologous Chondrocyte Therapy Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Osteoarthritis Autologous Chondrocyte Therapy Head Office and Area Served
- 6.4 Global Osteoarthritis Autologous Chondrocyte Therapy Players, Product Type & Application
- 6.5 Global Osteoarthritis Autologous Chondrocyte Therapy Manufacturers Established Date
- 6.6 Global Osteoarthritis Autologous Chondrocyte Therapy Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Osteoarthritis Autologous Chondrocyte Therapy Market Size (2021-2032)
- 7.2 North America Osteoarthritis Autologous Chondrocyte Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2021-2026)
- 7.4 North America Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Osteoarthritis Autologous Chondrocyte Therapy Market Size (2021-2032)
- 8.2 Europe Osteoarthritis Autologous Chondrocyte Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2021-2026)
- 8.4 Europe Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Osteoarthritis Autologous Chondrocyte Therapy Market Size (2021-2032)
- 9.2 Asia-Pacific Osteoarthritis Autologous Chondrocyte Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Osteoarthritis Autologous Chondrocyte Therapy Market Size (2021-2032)
- 10.2 South America Osteoarthritis Autologous Chondrocyte Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2021-2026)
- 10.4 South America Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Osteoarthritis Autologous Chondrocyte Therapy Market Size (2021-2032)
- 11.2 Middle East & Africa Osteoarthritis Autologous Chondrocyte Therapy Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Osteoarthritis Autologous Chondrocyte Therapy Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 CO.DON GmbH
- 12.1.1 CO.DON GmbH Company Information
- 12.1.2 CO.DON GmbH Business Overview
- 12.1.3 CO.DON GmbH Revenue in Osteoarthritis Autologous Chondrocyte Therapy Business (2021-2026)
- 12.1.4 CO.DON GmbH Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio
- 12.1.5 CO.DON GmbH Recent Developments
- 12.2 Japan Tissue Engineering
- 12.2.1 Japan Tissue Engineering Company Information
- 12.2.2 Japan Tissue Engineering Business Overview
- 12.2.3 Japan Tissue Engineering Revenue in Osteoarthritis Autologous Chondrocyte Therapy Business (2021-2026)
- 12.2.4 Japan Tissue Engineering Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio
- 12.2.5 Japan Tissue Engineering Recent Developments
- 12.3 Orthocell
- 12.3.1 Orthocell Company Information
- 12.3.2 Orthocell Business Overview
- 12.3.3 Orthocell Revenue in Osteoarthritis Autologous Chondrocyte Therapy Business (2021-2026)
- 12.3.4 Orthocell Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio
- 12.3.5 Orthocell Recent Developments
- 12.4 Vericel
- 12.4.1 Vericel Company Information
- 12.4.2 Vericel Business Overview
- 12.4.3 Vericel Revenue in Osteoarthritis Autologous Chondrocyte Therapy Business (2021-2026)
- 12.4.4 Vericel Osteoarthritis Autologous Chondrocyte Therapy Product Portfolio
- 12.4.5 Vericel Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst